Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019066435) ANTI-BCMA ANTIBODY HAVING HIGH AFFINITY FOR BCMA AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SAME
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/066435 International Application No.: PCT/KR2018/011318
Publication Date: 04.04.2019 International Filing Date: 21.09.2018
IPC:
C07K 16/28 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
재단법인 목암생명과학연구소 MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH [KR/KR]; 경기도 용인시 기흥구 이현로30번길 93 93, Ihyeon-ro 30beon-gil, Giheung-gu Yongin-si Gyeonggi-do 16924, KR
주식회사 녹십자 GREEN CROSS CORPORATION [KR/KR]; 경기도 용인시 기흥구 이현로30번길 107 107, Ihyeon-ro 30beon-gil, Giheung-gu Yongin-si Gyeonggi-do 16924, KR
Inventors:
최혜지 CHOI, Hye-Ji; KR
박재찬 PARK, Jae-Chan; KR
임형권 LIM, Hyung-Kwon; KR
Agent:
제일특허법인(유) FIRSTLAW P.C.; 서울특별시 서초구 마방로 60 60 Mabang-Ro Seocho-Ku Seoul 06775, KR
Priority Data:
10-2017-012799029.09.2017KR
Title (EN) ANTI-BCMA ANTIBODY HAVING HIGH AFFINITY FOR BCMA AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SAME
(FR) ANTICORPS ANTI-BCMA AYANT UNE AFFINITÉ ÉLEVÉE POUR BCMA ET COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DU CANCER, COMPRENANT CELUI-CI
(KO) BCMA에 높은 친화도를 가지는 항-BCMA 항체 및 이를 포함하는 암 치료용 약학적 조성물
Abstract:
(EN) Provided according to an embodiment of the present invention is an antibody that binds specifically to B-cell maturation antigen (BCMA) and comprises a heavy chain variable domain (VH domain) composed of a sequence having a homology of 80% or higher with any one of the amino acid sequences of SEQ ID NOS: 1 to 20, or a fragment thereof.
(FR) Selon un mode de réalisation, la présente invention concerne un anticorps qui se lie spécifiquement à l'antigène de maturation des lymphocytes B (BCMA) et comprend un domaine variable de chaînes lourdes (domaine VH) composée d'une séquence ayant une homologie de 80 % ou plus avec l'une quelconque des séquences d'acides aminés parmi les SEQ ID NOS: 1 à 20, ou un fragment de celle-ci.
(KO) 본 발명의 일 실시예에 따르면, 서열번호 1 내지 20 중 어느 하나의 아미노산 서열과 80% 이상의 상동성을 가지는 서열로 이루어진 중쇄 가변 영역 (VH domain)을 포함하는, BCMA(B-cell maturation antigen)에 특이적으로 결합하는 항체 또는 이의 단편이 제공된다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)